Technology to Improve the Detection of Cancer and Enhance Therapeutic Effectiveness
Armune BioScience has been involved in the research and development of diagnostic and prognostic tests for prostate, lung, and breast cancers that may allow physicians and patients to make more personalized treatment decisions for a better prognosis. The company utilized technology based on evidence that the immune system’s early warning signals provide critical biological insight to improve cancer detection and enhance therapeutic effectiveness.
The immune system response technology developed by Armune BioScience was acquired by Exact Sciences Corp. (Nasdaq: EXAS) on December 15, 2017. As of the date of the transaction, Armune BioScience is no longer offering laboratory testing services.